This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adams, M. Articles by Bell, S. C. Search for Related Content PubMed PubMed Citation Articles by Adams, M. Articles by Bell, S. C.

Changes in Tenascin-C Isoform Expression in Invasive and Preinvasive Breast Disease¹

University of Leicester, Breast Cancer Research Unit, Glenfield Hospital, Leicester LE3 9QP [M. A., J. L. J., R. A. W.]; Department of Pathology, University of Leicester, Leicester LE2 7LX [J. H. P.]; and Department of Obstetrics and Gynaecology, Leicester Royal Infirmary, Leicester LE2 7LX [S. C. B.], United Kingdom

Tenascin-C (TN) is an extracellular matrix protein that is expressed at low levels in normal adult tissue but is highly expressed around many tumors including breast carcinoma. TN exists as multiple isoforms generated through alternative splicing, and these isoforms have different effects on cell growth and migration. This study has analyzed in detail the pattern of TN isoform expression in benign, preinvasive, and invasive breast lesions using reverse transcription-PCR and Southern blotting. Significant differences in the profile of TN isoforms were identified. Although all tissues expressed the fully truncated TN, expression of two additional isoforms, one containing exon 16 (TN16) and one containing both exons 14 and 16 (TN14/16), were significantly associated with the invasive phenotype (P < 0.001). A subset of ductal carcinoma in situ (DCIS) cases were also found to express these isoforms, which may be indicative of a high risk of invasion in these lesions. Expression of these isoforms correlated with the presence of TN protein in the stroma in place of or in addition to basement membrane TN. Immunohistochemistry and in situ hybridization confirmed the production of exon 14-containing higher molecular weight isoforms by stromal fibroblasts in malignant tissue and both periductal fibroblasts and residual myoepithelial cells in DCIS. Although no evidence of tumor cell synthesis of TN was detected in the tissues, two highly invasive breast cancer cell lines (MDA-MB 231 and MDA-MB 468) were found to produce TN in contrast with tumor cells with a lower invasive capacity (MCF-7 and T47D).

These results demonstrate for the first time that specific TN isoforms are expressed in invasive breast carcinomas and that these isoforms are identified in a subset of DCIS and suggest that detection of TN16 and/or TN14/16 may be used as a predictor for invasion. Functional studies are now essential to establish the effect of these isoforms on tumor behavior and evaluate whether they will provide appropriate targets for therapeutic intervention.

This article has been cited by other articles:

				D. FISCHER, M. THOME, S. BECKER, T. CORDES, K. DIEDRICH, M. FRIEDRICH, and M. THILL 25-Hydroxyvitamin D3 1{alpha}-Hydroxylase Splice Variants in Benign and Malignant Ovarian Cell Lines and Tissue Anticancer Res, September 1, 2009; 29(9): 3627 - 3633. [Abstract] [Full Text] [PDF]

				M. SEIFERT, W. TILGEN, and J. REICHRATH Expression of 25-Hydroxyvitamin D-1{alpha}-Hydroxylase (1{alpha}OHase, CYP27B1) Splice Variants in HaCaT Keratinocytes and Other Skin Cells: Modulation by Culture Conditions and UV-B Treatment In Vitro Anticancer Res, September 1, 2009; 29(9): 3659 - 3667. [Abstract] [Full Text] [PDF]

				A. M. Sotoca Covaleda, H. van den Berg, J. Vervoort, P. van der Saag, A. Strom, J.-A. Gustafsson, I. Rietjens, and A. J. Murk Influence of Cellular ER{alpha}/ER{beta} Ratio on the ER{alpha}-Agonist Induced Proliferation of Human T47D Breast Cancer Cells Toxicol. Sci., October 1, 2008; 105(2): 303 - 311. [Abstract] [Full Text] [PDF]

				J. Helleman, M. P.H.M. Jansen, K. Ruigrok-Ritstier, I. L. van Staveren, M. P. Look, M. E. Meijer-van Gelder, A. M. Sieuwerts, J. G.M. Klijn, S. Sleijfer, J. A. Foekens, et al. Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response Clin. Cancer Res., September 1, 2008; 14(17): 5555 - 5564. [Abstract] [Full Text] [PDF]

				J. D. Fackenthal and L. A. Godley Aberrant RNA splicing and its functional consequences in cancer cells Dis. Model. Mech., July 1, 2008; 1(1): 37 - 42. [Abstract] [Full Text] [PDF]

				M. Degen, F. Brellier, R. Kain, C. Ruiz, L. Terracciano, G. Orend, and R. Chiquet-Ehrismann Tenascin-W Is a Novel Marker for Activated Tumor Stroma in Low-grade Human Breast Cancer and Influences Cell Behavior Cancer Res., October 1, 2007; 67(19): 9169 - 9179. [Abstract] [Full Text] [PDF]

				S. S. Brack, M. Silacci, M. Birchler, and D. Neri Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin. Cancer Res., May 15, 2006; 12(10): 3200 - 3208. [Abstract] [Full Text] [PDF]

				L. Milani, M. Fredriksson, and A.-C. Syvanen Detection of Alternatively Spliced Transcripts in Leukemia Cell Lines by Minisequencing on Microarrays Clin. Chem., February 1, 2006; 52(2): 202 - 211. [Abstract] [Full Text] [PDF]

				B. Diesel, J. Radermacher, M. Bureik, R. Bernhardt, M. Seifert, J. Reichrath, U. Fischer, and E. Meese Vitamin D3 Metabolism in Human Glioblastoma Multiforme: Functionality of CYP27B1 Splice Variants, Metabolism of Calcidiol, and Effect of Calcitriol Clin. Cancer Res., August 1, 2005; 11(15): 5370 - 5380. [Abstract] [Full Text] [PDF]

				L. Orlando, G. Renne, A. Rocca, G. Curigliano, M. Colleoni, G. Severi, G. Peruzzotti, S. Cinieri, G. Viale, G. Sanna, et al. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype Ann. Onc., July 1, 2005; 16(7): 1094 - 1099. [Abstract] [Full Text] [PDF]

				S. Suwiwat, C. Ricciardelli, R. Tammi, M. Tammi, P. Auvinen, V.-M. Kosma, R. G. LeBaron, W. A. Raymond, W. D. Tilley, and D. J. Horsfall Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer Clin. Cancer Res., April 1, 2004; 10(7): 2491 - 2498. [Abstract] [Full Text] [PDF]

				T. Tsunoda, H. Inada, I. Kalembeyi, K. Imanaka-Yoshida, M. Sakakibara, R. Okada, K. Katsuta, T. Sakakura, Y. Majima, and T. Yoshida Involvement of Large Tenascin-C Splice Variants in Breast Cancer Progression Am. J. Pathol., June 1, 2003; 162(6): 1857 - 1867. [Abstract] [Full Text] [PDF]

				H Chauhan, A Abraham, J R A Phillips, J H Pringle, R A Walker, and J L Jones There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions J. Clin. Pathol., April 1, 2003; 56(4): 271 - 276. [Abstract] [Full Text] [PDF]

				Z. Wang, H. S. Lo, H. Yang, S. Gere, Y. Hu, K. H. Buetow, and M. P. Lee Computational Analysis and Experimental Validation of Tumor-associated Alternative RNA Splicing in Human Cancer Cancer Res., February 1, 2003; 63(3): 655 - 657. [Abstract] [Full Text] [PDF]

				D. Martin, M. Brown-Luedi, and R. Chiquet-Ehrismann Tenascin-C signaling through induction of 14-3-3 tau J. Cell Biol., January 21, 2003; 160(2): 171 - 175. [Abstract] [Full Text] [PDF]